In vitro and in vivo activity of SC-560 in comparison to celecoxib against colorectal cancer cells was investigated by Grosch S. et al. [153], by evaluating their effects on survival, cell cycle progression, and apoptosis of colon cancer cell characterized for COX-1 and COX-2 expression. This evidence concerns the gene PTGS1 and colorectal cancer.